SMAC mimetic BV6 enables sensitization of resistant tumor cells but also affects cytokine-induced killer (CIK) cells: a potential challenge for combination therapy

• Main Authors: Eva eRettinger (Author), Andreas eGlatthaar (Author), Behnaz eAhangarian Abhari (Author), Sarah eOelsner (Author), Verena ePfirrmann (Author), Sabine eHuenecke (Author), Selim eKuci (Author), Hermann eKreyenberg (Author), Andre M Willasch (Author), Thomas eKlingebiel (Author), Simone eFulda (Author), Peter eBader (Author)
• Format: Book
• Published: Frontiers Media S.A., 2014-07-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Allogeneic hematopoietic stem cell transplantation (HSCT) is an established treatment option for high-risk hematological malignancies, and may also be offered to patients with solid malignancies refractory to conventional therapies. In case of patients' relapse, refractory tumor cells may then...